Panel Title: “Therapeutic Insight: Immuno-Oncology’s Next Generation Therapies”

NEW YORK, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, announced today that William Ho, President and Chief Executive Officer of Incysus, will participate in the “Therapeutic Insight: Immuno-Oncology’s Next Generation Therapies” panel at the 2018 Life Sciences Summit (https://lifesciencessummit.org/2018-agenda/).  He will join a distinguished group of panelists including representatives from Merck, Bristol-Myers Squibb, Quentis Therapeutics and Memorial Sloan-Kettering Cancer Center. The panel, moderated by Jeffrey M. Brockman, PhD, Executive Vice President, Head of Oncology Practice, Defined Health, will be held on Wednesday, October 24, 2018, at 10:00 am EDT at “10 On The Park” in New York City. 

Who:  William Ho, President and Chief Executive Officer
What:  Incysus Participation in Immuno-Oncology Panel at the Life Sciences Summit
When:  Wednesday, October 24, 2018 at 10:00 am EDT
Where:  “10 On The Park,” 60 Columbus Circle, New York, NY 10019

About Life Sciences Summit
The Life Sciences Summit is an early-stage investor and business development conference for emerging companies and academic innovators. The objective of the meeting is to connect emerging companies with early-stage investors, business development professionals, and medical research foundations with the goal of advancing new innovations through clinical development.

About Incysus Therapeutics, Inc.
Incysus is focused on delivering a novel off-the-shelf cell therapy for the treatment of cancer. By using genetically modified gamma-delta (γδ) T cells, the Company’s technology addresses the challenges that immunotherapies face targeting cold, low mutation cancers. Incysus’ immuno-oncology programs include activated and gene-modified adoptive cellular therapies that protect cells from chemotherapy and allow novel combinations to disrupt the tumor microenvironment and more selectively target cancer cells. Since the Company’s inception in early 2016, Incysus has filed two Investigational New Drug applications (IND) and has initiated several cancer programs in early pre-clinical stages.  The Company’s first program is targeted to leukemia and lymphoma patients and the IND related to this program was accepted by the FDA in late 2017.  The Company’s second program is targeted to treat patients with newly-diagnosed glioblastoma (GBM).  In collaboration with the University of Alabama at Birmingham (UAB), Incysus has advanced its technology and expects to begin both Phase 1 trials early next year.  For more information, visit www.incysus.com.

Contact:
Incysus Therapeutics, Inc.
(646) 820-8474
info@incysus.com